22157.jpg
Global Antibiotic Resistance Market Report 2022: New Technologies and New Drugs are Under Development to Capture this Growing Market
April 14, 2022 04:08 ET | Research and Markets
Dublin, April 14, 2022 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
22157.jpg
Global Antibiotic Resistance Markets Report 2021: Therapeutic Technology Development Opportunities by Pathogen and Therapy Type 2020-2024
August 31, 2021 05:53 ET | Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type 2020 to 2024" report has been added to ResearchAndMarkets.com's offering. ...
Summit Master_rgb_png.png
Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority
May 18, 2021 07:00 ET | Summit Therapeutics Inc.
Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738 (“SMT-738”), for development in the fight against...
ezgif.com-gif-maker.png
Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.
January 26, 2021 08:00 ET | Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
red.jpg
RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication
October 26, 2020 09:00 ET | RedHill Biopharma Ltd.
 H. pylori eradication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial, with antibiotic resistance a contributing factor. Despite declining...
provectus_logo.jpg
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee Health Science Center to Investigate Small Molecule Rose Bengal Disodium for Antibiotic Resistance
September 09, 2020 08:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Michio Kurosu, PhD, Professor,...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
September 03, 2020 21:42 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance
March 11, 2020 13:00 ET | Deinove
DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance The AGIR program, supported by the French Investments for the Future program, aims to accelerate new...
Phase Genomics Receives $1.5MM NIH Grant to Develop Fast and Affordable Commercial Antimicrobial Resistance Tracking Kit
January 08, 2020 09:30 ET | Phase Genomics
SEATTLE, Washington, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Phase Genomics, Inc., the biotech leader providing proximity-ligation next-generation sequencing (NGS) solutions for metagenome assembly, today...
ezgif.com-gif-maker.png
Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer
October 30, 2019 16:05 ET | Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat...